论文部分内容阅读
目的:建立卵巢癌患者血清差异表达多肽谱,并探讨其潜在诊断价值。方法:应用磁珠富集多肽结合基质辅助激光解吸电离飞行时间质谱(matrix-assisted laser desorption/ionization time-of-flight mass spectrometry,MALDI-TOF-MS)检测方法,筛选上皮性卵巢癌组和健康对照组差异表达多肽峰,利用ClinProTools软件比较两组血清多肽表达差异并建立差异表达多肽谱及早期诊断模型。结果:在卵巢癌组血清中,m/z 2 662.02、2 653.68、5 859.21、5 901.69、5 937.06表达显著上调;m/z 1 857.82、2 074.28、2 856.33表达显著下调。差异表达图谱建立的诊断模型预测早期卵巢癌的准确率达到81.8%(9/11),利用9例宫颈癌血清验证均为阴性,特异性达100%(0/9)。结论:磁珠富集-质谱结合ClinProTools生物信息学分析技术,有望成为新的人卵巢癌辅助诊断技术。
Objective: To establish a serum differentially expressed peptide profile in patients with ovarian cancer and to explore its potential diagnostic value. Methods: The epithelial ovarian cancer and healthy controls were screened by matrix-assisted laser desorption / ionization time-of-flight mass spectrometry (MALDI-TOF-MS) The control group differentially expressed peptide peaks. ClinProTools software was used to compare the difference of serum polypeptide expression between the two groups and the establishment of differentially expressed peptide profiles and early diagnosis models. Results: The levels of m / z 2 662.02, 2 653.68, 5 859.21, 5 901.69 and 5 937.06 were significantly up-regulated in the ovarian cancer group. The m / z 1 857.82, 2 074.28 and 2 856.33 were significantly down-regulated. The diagnostic model established by differential expression profiling predicted the accuracy of early ovarian cancer to 81.8% (9/11), and was negative in 9 cases of cervical cancer. The specificity was 100% (0/9). Conclusion: Magnetic bead enrichment-mass spectrometry coupled with ClinProTools bioinformatics analysis technology is expected to become a new diagnostic technique for human ovarian cancer.